Lamisil Once

Terbinafine Hydrochloride, the active ingredient in Lamisil Once, is an allylamine antifungal presented as a topical formulation for skin use. It treats superficial dermatophyte infections such as athlete’s foot, ringworm and jock itch in adults and children.

GNH USA supplies Lamisil Once as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil Once (terbinafine) is used to treat superficial fungal infections caused by dermatophytes.

- Tinea corporis: clears ring‑shaped skin lesions caused by dermatophytes. - Tinea pedis: resolves itching, scaling and redness of athlete’s foot. - Tinea cruris: alleviates jock itch symptoms and eradicates the underlying fungus. - Superficial dermatophyte infections: eliminates fungal colonisation on the skin surface.

Common Side Effects: - Itching at the application site. - Burning sensation during or after application. - Redness or erythema of the treated skin. - Dryness or flaking of the skin. - Mild irritation or stinging. - Scaling or peeling of the skin.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Contact dermatitis with extensive swelling. - Blistering or bullous eruptions. - Urticaria (hives). - Angioedema of the face or lips. - Stevens‑Johnson syndrome or toxic epidermal necrolysis (very rare).

Before using Lamisil Once, consider the following precautions.

- Apply to intact skin only: avoid broken or inflamed areas. - Avoid contact with eyes: rinse thoroughly if accidental exposure occurs. - Do not combine with other topical antifungals unless directed by a healthcare professional. - Discontinue use if severe irritation or allergic reaction develops: seek medical advice. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Terbinafine topical has limited systemic interactions, but awareness of concomitant therapies is important.

Major Interactions (Avoid): - Concurrent systemic terbinafine therapy: risk of cumulative systemic exposure. - Use with other topical irritants (e.g., corticosteroids) without medical guidance.

Moderate Interactions (Monitor Closely): - Co‑application with other antifungal creams may reduce overall efficacy. - Use with occlusive dressings may increase percutaneous absorption. - Patients on warfarin: monitor INR if systemic absorption is suspected.